Ketamine is a wonder drug. Ketamine is a tool of systemic racism. Ketamine is impossible to overdose. Ketamine is an inappropriate drug used for inappropriate purposes. So much controversy. What should we believe? When in doubt, follow the data. Dr. Jeff Jarvis reviews a very timely paper just released in Annals of Emergency Medicine using the 2019 Data Collaborative data set that aims to describe the characteristics of patients getting ketamine as well as the potential deaths associated with it. As an added bonus, Drs. Remle Crowe and Brent Myers join Dr. Jarvis for an interview about their paper and the controversies surrounding ketamine use.
More episodes from "The EMS Lighthouse Project"
Episode 52 – The BOUGIE Trial
31:17Do you even bougie, bro? Do you use the bougie on every intubation? If so, why? Do you think it improves first pass success? Well, I certainly did. At least before this trial was released. Join me to discuss this randomized controlled trial of bougie vs no bougie for intubation. I suspect the results will surprise you!
Episode 51 – Abstracts from PCRF at EMS Expo 2021 - Part 2
1:00:56Dr. Jarvis and Mike Verkest return for part 2 of our interviews with some of the great researchers at the Prehospital Care Research Forum at EMS Expo in Atlanta. In this episode, we interview: Kevin Collopy on his RCT comparing ketamine and etomidate for RSI, Sean McAllister on Sepsis using the ESO dataset, and David Page about PCRF and his work on comparing Mexican and American EMT training. If you like the show, please give us a like on YouTube and a 5-star rating wherever you get your podcasts.
Episode 50 – PCRF Research Abstracts from EMS Expo – Part I
39:10Dr. Jarvis and Mike Verkest were at EMS Expo in Atlanta. We recorded some interviews from the FlightbridgeED booth on the exhibit floor and then discussed them when Mike stopped by the Casa Jarvis in Austin a bit later. There was so much goodness, we broke it up into two different episodes to keep these at a reasonable length.
Episode 49 – The RACKED Trial, with Dr. Barbic
1:14:08Ketamine has been getting a lot of attention recently in the media. Its probably safe to say it’s had a bad year. We like ketamine. We felt bad it’s been having a rough year so we wanted to do something that would lift its spirits. Fortunately, Dr. David Barbic and his colleagues from Vancouver, BC published a wonderful, randomized trial comparing ketamine to a combination of haloperidol plus midazolam for undifferentiated agitation in the ED. This was the amazingly titled RACKED trial (Rapid Agitation Control with Ketamine in the ED). It has direct and important implications for EMS and is something all emergency providers should know about. Dr. Jarvis reviews the trial and then invites Dr. Barbic himself on the show to discuss this study. If you like the show, please give us a like on YouTube and a 5-star rating wherever you get your podcasts.
Episode 48 – Airway Updates from NEAR
50:31Mike and Jeff get together to discuss some airway papers from the National Emergency Airway Registry (NEAR) and float an idea for some merch.If you like the show, please give us a like on YouTube and a 5-star rating wherever you get your podcasts. Drop us questions/comments/suggestion for future pods at: [email protected], @DrJeffJarvis, or [email protected], @MikeVerkest
Episode 47 – ETI Attempts and Outcomes in Out of Hospital Cardiac Arrest
22:38In this episode, Dr. Jarvis discusses a paper that is hot off the presses and that he’s super excited to talk about. The good folks up in Seattle, WA and the Seattle FD looked at their cardiac arrest survival rates as a function of the number of intubation attempts needed to secure the airway. Results from this trial might help explain the 2.9% improved survival with King LT vs ETI that we saw in the PART trial. Join us to hear all the juicy details. As always, if you like the pod, give us a 5-star rating wherever you get your pods. If you have any questions, drop us a note: [email protected] or @DrJeffJarvis and [email protected] or @MikeVerkest. You can also follow the pod on Twitter at @EMSLighthouseProject.
Episode 46: 2020 EMS LLSA Review with Dr. Casey Patrick
1:17:42Every other year board certified EMS physicians must take an open book quiz over 20-25 papers felt by the American Board of Emergency Medicine (ABEM) to be something all EMS physicians should know. Dr. Jarvis and Dr. Casey Patrick (@cpatrick_89) from Montgomery County Health District EMS gave a lecture reviewing the 2020 ABEM EMS LLSA articles at the recent meeting of the Texas Chapter of NAEMSP. We got together right after our lecture to record this podcast going over these articles. Join us from the Cavalier Room at the Historic Menger Hotel (@mengerhotel) in downtown San Antonio, literally next door to the Alamo.
Episode 45: ESO Ketamine Paperfrom Eagles
1:26:38Ketamine is a wonder drug. Ketamine is a tool of systemic racism. Ketamine is impossible to overdose. Ketamine is an inappropriate drug used for inappropriate purposes. So much controversy. What should we believe? When in doubt, follow the data. Dr. Jeff Jarvis reviews a very timely paper just released in Annals of Emergency Medicine using the 2019 Data Collaborative data set that aims to describe the characteristics of patients getting ketamine as well as the potential deaths associated with it. As an added bonus, Drs. Remle Crowe and Brent Myers join Dr. Jarvis for an interview about their paper and the controversies surrounding ketamine use.
Episode 44: OHCA Update from Bend, OR
46:41What is the impact of on-scene resuscitation vs intra-arrest transport on outcomes? Could the differences in first pass success between ETI and King LT have accounted for the differences in outcome in the PART trial? How about differences in compression interruptions? In this episode recorded on the road in Bend, Oregon, Dr. Jarvis reviews three new papers that address just these questions. He then has an interview and Petar and Amber Hossick about how Bend Fire Rescue has implemented tenets of improvement science to impact survival in their community.
Episode 43: mRNA Vaccines – Real World Efficacy
17:33We saw the amazing performance of the two mRNA COVID vaccines from Pfizer and Moderna in their RCTs. As encouraging as trial performance is, we always want to see how those numbers hold up under large-scale, real-world pragmatic conditions. Well, we now have three new pieces of information on that. And, for the cherry on top, we get evidence of performance against asymptomatic infection! Dr. Jarvis does a quick review of the latest evidence on vaccine performance.